Clover Biopharmaceuticals, Ltd, a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and ...
CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variati...
Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
AstraZeneca announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manu...
Terumo Neuro, a global leader in neurovascular innovation and a wholly-owned subsidiary of Terumo Corporation, proudly celebrates the 15th anniversary of t...
Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned s...
Paratek Pharmaceuticals and Optinose, Inc. announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, includ...
Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleas...
TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 long-acting dual bNAb regime...
Dyne Therapeutics, Inc., a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscul...
AbbVie announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab s...
Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), announced its investment in Illexcor Ther...
GC Cell, under the leadership of CEO Sungyong Won, announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5...
Gilead Sciences, Inc. presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company...
© 2025 Biopharma Boardroom. All Rights Reserved.
